Flow Cytometric Measurement of Blood Cells with BCR-ABL1 Fusion Protein in Chronic Myeloid Leukemia
Abstract Chronic myeloid leukemia (CML) is characterized in the majority of cases by a t(9;22)(q34;q11) translocation, also called the Philadelphia chromosome, giving rise to the BCR-ABL1 fusion protein. Current treatment with tyrosine kinase inhibitors is directed against the constitutively active...
Guardado en:
Autores principales: | Liza Löf, Linda Arngården, Ulla Olsson-Strömberg, Benjamin Siart, Mattias Jansson, Joakim S. Dahlin, Ingrid Thörn, Lisa Christiansson, Monica Hermansson, Anders Larsson, Erik Ahlstrand, Göran Wålinder, Ola Söderberg, Richard Rosenquist, Ulf Landegren, Masood Kamali-Moghaddam |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bc40746d211b48e79b0577d852b7ebdb |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A Novel ELISA-Based Peptide Biosensor Assay for Screening ABL1 Activity in vitro: A Challenge for Precision Therapy in BCR-ABL1 and BCR-ABL1 Like Leukemias
por: Oksana Montecchini, et al.
Publicado: (2021) -
Major molecular response achievement in CML Patients can be predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS ratio at an earlier time point of follow-up than currently recommended.
por: Sarah Huet, et al.
Publicado: (2014) -
Characteristics of BCR–ABL gene variants in patients of chronic myeloid leukemia
por: Amin Huma, et al.
Publicado: (2021) -
Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
por: Diletta Fontana, et al.
Publicado: (2021) -
Regulatory effects of sestrin 3 (SESN3) in BCR-ABL expressing cells.
por: Eliza Vakana, et al.
Publicado: (2013)